• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
6,124 results

Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.

Docket 23-1977, U.S. Court of Appeals, Federal Circuit (June 5, 2023)
Patent - Abbreviated New Drug Application (ANDA)
Case Type835 Patent - Abbreviated New Drug Application (ANDA)
Tags835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda
Plaintiff - Appellant AZURITY PHARMACEUTICALS, INC.
Defendant - Appellee ALKEM LABORATORIES LTD.
cite Cite Docket
Analyze

Celgene Corporation v. Hetero Labs Limited

Docket 21-2335, U.S. Court of Appeals, Federal Circuit (Sept. 21, 2021)
Patent
Case Type830 Patent
Tags830 Patent, 830 Patent
Plaintiff - Appellant CELGENE CORPORATION
Defendant HETERO LABS LIMITED
Defendant HETERO LABS LIMITED UNIT-V
...
cite Cite Docket
Analyze

Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.

Docket 1:23-cv-01015, Delaware District Court (Sept. 15, 2023)
Judge William C. Bryson, presiding
Patent - Abbreviated New Drug Application (ANDA)
DivisionWilmington
FlagsPATENT
Cause35:271 Patent Infringement
Case Type835 Patent - Abbreviated New Drug Application (ANDA)
Tags835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda
DeadlineIT IS HEREBY STIPULATED AND AGREED, by the parties, subject to the approval of the Court, that the following deadlines shall be modified as follows to accommodate the availability of the parties’ fact witnesses and to adjust the deadline for Case Dispositive Motions and Daubert Motions to the same deadline because the Scheduling Order requires them to be briefed together (D.I. 38 at ¶ 14): Event Currently Noticed Depositions Opening Expert Reports Responsive Expert Reports Reply Expert Reports Close of Expert Discovery Case Dispositive Motions Daubert Motions Trial Current Deadline N/A October 28, 2024 December 2, 2024 January 6, 2025 February 10, 2025 February 24, 2025 February 27, 2025 May 19, 2025 Stipulated Proposal October 22, 2024 November 15, 2024 December 20, 2024 January 17, 2025 February 21, 2025 February 28, 2025 February 28, 2025 May 19, 2025 (unchanged) No other deadlines in the Scheduling Order shall be affected by this stipulation., A 5 Day Bench Trial is set for 5/19/2025 - 5/23/2025 at 08:30 AM in To Be Determined before Judge William C. Bryson.
DeadlineA 5 Day Bench Trial is set for 5/19/2025 - 5/23/2025 at 08:30 AM in To Be Determined before Judge William C. Bryson.
Plaintiff Heron Therapeutics, Inc.
Defendant Mylan Pharmaceuticals Inc.
Counter Claimant Mylan Pharmaceuticals Inc.
...
cite Cite Docket
Analyze

Sanofi-Aventis U.S. LLC v. Mylan GmbH

Docket 21-1262, U.S. Court of Appeals, Federal Circuit (Nov. 19, 2020)
Patent - Abbreviated New Drug Application (ANDA)
08/03/2021
... Appellees Biocon Ltd., Biocon Research Ltd., Biocon S.A., Biocon Sdn.Bhd and Mylan GmbH regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790319] [21-1262] [...
cite Cite Docket
Analyze

Celgene Corporation v. Mylan Pharmaceuticals Inc.

Docket 21-1154, U.S. Court of Appeals, Federal Circuit (Nov. 5, 2020)
Patent - Abbreviated New Drug Application (ANDA)
05/11/2021
05/11/2021 38 Notice from Appellant Celgene Corporation regarding conflicts with oral argument. None. Service: 05/11/2021 by email. [774398] [21-1154] [Ellyde Th...
cite Cite Docket
Analyze

Mylan Pharmaceuticals Inc. v. Bayer Intellectual Property GMBH et al

Docket 1:23-cv-00556, Delaware District Court (May 19, 2023)
Judge Richard G. Andrews, presiding
Patent - Abbreviated New Drug Application (ANDA)
DivisionWilmington
FlagsPATENT
Cause35:1 Patent Infringement
Case Type835 Patent - Abbreviated New Drug Application (ANDA)
Tags835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda
DeadlineWhen the ’053 Patent expires, Mylan says that the FDA’s “longstanding practice” will convert Mylan’s ParagraphIVcertification into a ParagraphII certification® and cause a new pediatric exclusivity period to attach to the 053 Patent, foreclosing final approval until May 13, 2025., But Defendants cannotseriously dispute that, if Mylan were to obtain a judgmentof non-infringement on the ’053 Patent prior to November13, 2024, Mylan would have “prevailed”in its CAPC action, accelerating the timing of final approval to after February 28, 2025 (when pediatric exclusivity as to the °456 Patent expires), rather than after May 13, 2025 (when pediatric exclusivity as to the °053 Patent expires).
Plaintiff Mylan Pharmaceuticals Inc.
Defendant Bayer Intellectual Property GMBH
Defendant Bayer AG
...
cite Cite Docket
Analyze

Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals, Inc.

Docket 20-2071, U.S. Court of Appeals, Federal Circuit (July 27, 2020)
08/09/2021
08/09/2021 90 Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 08/09/2021 by email. [791343] [20-2071] [Daniel Kazhd...
08/03/2021
08/03/2021 88 Notice from Appellee Mylan Pharmaceuticals, Inc. regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790325] [20-2071] [Ric...
cite Cite Docket
Analyze

Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals Inc.

Docket 20-2066, U.S. Court of Appeals, Federal Circuit (July 27, 2020)
08/09/2021
08/09/2021 70 Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 08/09/2021 by email. [791340] [20-2066] [Brian Racilla...
08/03/2021
08/03/2021 68 Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790320] [20-2066] [Rich...
cite Cite Docket
Analyze
1 2 3 4 5 ... >>